Advertisement

Molecular profiling of key driver genes improves staging accuracy in multifocal non–small cell lung cancer

Published:December 20, 2019DOI:https://doi.org/10.1016/j.jtcvs.2019.11.126

      Abstract

      Objective

      Multifocal non–small cell lung cancer has historically been separated into synchronous primary lung cancers or intrapulmonary metastases with the use of histopathology. We hypothesize that using targeted next-generation sequencing of key driver mutations in multifocal non–small cell lung cancer will improve our ability to differentiate intrapulmonary metastases from synchronous primary lung cancers.

      Methods

      We identified patients who underwent surgery for non–small cell lung cancer between 2013 and 2018 with multifocal tumors. Archived specimens were reviewed with a 4-gene next-generation sequencing panel identifying mutations of EGFR, KRAS, BRAF, and NRAS. Synchronous primary lung cancers were classified as lesions with different histopathologic subtypes or driver mutations. Tests of hypotheses were performed with the Fisher exact test. Calculations were performed in Stata (v13.0; StataCorp LLC, College Station, Tex).

      Results

      A total of 18 patients had non–small cell lung cancer tumor specimens (n = 41) available from 2 or more sites. The pathologic diagnosis was predominantly adenocarcinoma (39/41 specimens). We detected a driver mutation in 68.3% (28/41) of all tumors. The most common mutations observed were in KRAS (n = 17/41) and EGFR (n = 7/41). Eleven patients had synchronous primary lung cancers, and 4 patients had intrapulmonary metastases based on combined histopathologic and molecular profiling results. Three lacked driver mutations in either lesion. Eight synchronous primary lung cancers (8/18, 44%) were downstaged when compared with their original diagnosis (P = .08). Of these, 4 patients received adjuvant chemotherapy unnecessarily in hindsight.

      Conclusions

      Molecular non–small cell lung cancer profiling using a 4-gene next-generation sequencing panel allows for better distinction between synchronous primary lung cancers and intrapulmonary metastases than histopathology alone. Routine use of next-generation sequencing for multifocal lesions prevents unnecessary adjuvant treatment for patients with histologically similar synchronous primary lung cancers.

      Graphical abstract

      Key Words

      Abbreviations and Acronyms:

      IASLC (International Association for the Study of Lung Cancer), IN (inconclusive), IPM (intrapulmonary metastasis), NGS (next-generation sequencing), NSCLC (non–small cell lung cancer), SPLC (synchronous primary lung cancer)
      To read this article in full you will need to make a payment

      References

        • Rami-Porta R.
        • Asamura H.
        • Travis W.D.
        • Rusch V.W.
        Amin M.B. Edge S. Greene F. Byrd D.R. Brookland R.K. Washington M.K. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing, Paris, France2017: 431-456
        • Antakli T.
        • Schaefer R.F.
        • Rutherford J.E.
        • Read R.C.
        Second primary lung cancer.
        Ann Thorac Surg. 1995; 59: 863-867
        • National Comprehensive Cancer Network
        NCCN guidelines - non-small cell lung cancer (Version 4.2019).
        (Available at:)
        • Martini N.
        • Melamed M.R.
        Multiple primary lung cancers.
        J Thorac Cardiovasc Surg. 1975; 70: 606-612
        • Cheng H.
        • Lei B.
        • Peng P.
        • Lin Y.
        • Wang X.
        Histologic lung cancer subtype differentiates synchronous multiple primary lung adenocarcinomas from intrapulmonary metastases.
        J Surg Res. 2017; 211: 215-222
        • Jamal-Hanjani M.
        • Wilson G.A.
        • McGranahan N.
        • Birkbak N.J.
        • Watkins T.B.K.
        • Veeriah S.
        • et al.
        • TRACERx Consortium
        Tracking the evolution of non-small-cell lung cancer.
        N Engl J Med. 2017; 376: 2109-2121
        • Eguren-Santamaria I.
        • Sanchez-Bayona R.
        • Patiño-Garcia A.
        • Gil-Bazo I.
        • Lopez-Picazo J.M.
        Targeted DNA sequencing for assessing clonality in multiple lung tumors: a new approach to an old dilemma.
        Lung Cancer. 2018; 122: 120-123
        • Murphy S.J.
        • Aubry M.
        • Harris F.R.
        • Halling G.C.
        • Johnson S.H.
        • Terra S.
        • et al.
        Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non–small-cell lung cancer.
        J Clin Oncol. 2014; 32: 4050-4058
        • Nicholson A.G.
        • Torkko K.
        • Viola P.
        • Duhig E.
        • Geisinger K.
        • Borczuk A.C.
        • et al.
        Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung.
        J Thorac Oncol. 2018; 13: 205-217
        • Chapman A.M.
        • Sun K.Y.
        • Ruestow P.
        • Cowan D.M.
        • Madl A.K.
        Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers.
        Lung Cancer. 2016; 102: 122-134
        • Chuang J.C.
        • Shrager J.B.
        • Wakelee H.A.
        • Neal J.W.
        Concordant and discordant EGFR mutations in patients with multifocal adenocarcinomas: Implications for EGFR-targeted therapy.
        Clin Ther. 2016; 38: 1567-1576
        • Lau D.H.
        • Yang B.
        • Hu R.
        • Benfield J.R.
        Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysis.
        Diagn Mol Pathol. 1997; 6: 179-184
        • Matsuzoe D.
        • Hideshima T.
        • Ohshima K.
        • Kawahara K.
        • Shirakusa T.
        • Kimura A.
        Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation.
        Br J Cancer. 1999; 79: 1549-1552
        • Ulivi P.
        • Chiadini E.
        • Dazzi C.
        • Dubini A.
        • Costantini M.
        • Medri L.
        • et al.
        Nonsquamous, Non-small-cell lung cancer patients who carry a double mutation of EGFR, EML4-ALK or KRAS: frequency, clinical-pathological characteristics, and response to therapy.
        Clin Lung Cancer. 2016; 17: 384-390
        • Detterbeck F.C.
        • Bolejack V.
        • Arenberg D.A.
        • Crowley J.
        • Donington J.S.
        • Franklin W.A.
        • et al.
        The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.
        J Thorac Oncol. 2016; 11: 681-692
        • Girard N.
        • Deshpande C.
        • Lau C.
        • Finley D.
        • Rusch V.
        • Pao W.
        • et al.
        Comprehensive histologic assessment helps to differentiate multiple lung primary non-small cell carcinomas from metastases.
        Am J Surg Pathol. 2009; 33: 1752
        • Shan S.
        • She J.
        • Xue Z.
        • Su C.
        • Ren S.
        • Wu F.
        Clinical characteristics and survival of lung cancer patients associated with multiple primary malignancies.
        PLoS One. 2017; 12: e0185485
        • Lindeman N.I.
        • Cagle P.T.
        • Beasley M.B.
        • Chitale D.A.
        • Dacic S.
        • Giaccone G.
        • et al.
        Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
        J Thorac Oncol. 2013; 8: 823
        • Jia X.
        • Zhang L.
        • Wu W.
        • Zhang W.
        • Wu C.
        Driver mutation analysis and PD-L1 expression in synchronous double primary lung cancer.
        Appl Immunohistochem Mol Morphol. 2018; 26: 246-253
        • Oun R.
        • Moussa Y.E.
        • Wheate N.J.
        The side effects of platinum-based chemotherapy drugs: a review for chemists.
        Dalton Trans. 2018; 47: 6645-6653
        • Lee C.K.
        • Brown C.
        • Gralla R.J.
        • Hirsh V.
        • Thongprasert S.
        • Tsai C.
        • et al.
        Impact of EGFR inhibitor in Non–Small cell lung cancer on progression-free and overall survival: A meta-analysis.
        J Natl Cancer Inst. 2013; 105: 595-605
        • Patel S.B.
        • Kadi W.
        • Walts A.E.
        • Marchevsky A.M.
        • Pao A.
        • Aguiluz A.
        • et al.
        Next-generation sequencing: a novel approach to distinguish multifocal primary lung adenocarcinomas from intrapulmonary metastases.
        J Mol Diagn. 2017; 19: 870-880
        • Quéré G.
        • Descourt R.
        • Robinet G.
        • Autret S.
        • Raguenes O.
        • Fercot B.
        • et al.
        Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
        BMC Cancer. 2016; 16: 210
        • Zhou X.
        • Tian L.
        • Fan J.
        • Lai Y.
        • Li S.
        • Che G.
        • et al.
        Method for discriminating synchronous multiple lung cancers of the same histological type: miRNA expression analysis.
        Medicine (Baltimore). 2016; 95: e4478
        • Wang S.X.Y.
        • Lei L.
        • Guo H.H.
        • Shrager J.
        • Kunder C.A.
        • Neal J.W.
        Synchronous primary lung adenocarcinomas harboring distinct MET exon 14 splice site mutations.
        Lung Cancer. 2018; 122: 187-191